Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids

Pujols, Laura; Alobid, Isam; Benítez, Pedro; Martínez-Antón, Asunción; Roca‐Ferrer, Jordi; Fokkens, Wytske J.; Mullol, Joaquim; Picado, César

doi:10.1111/j.1398-9995.2008.01745.x

Cited by 50 publications

(73 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Pujols's study, the patients with nasal polyps were divided into GCtreated and untreated groups. 16 Even though there were steroid-insensitive individuals in the GC-treated group, because of the relatively small number, quantitative values of GRα and GRβ expression from such patients were likely masked by GRα and GRβ expression level in the majority of GC-sensitive patients. It may therefore be difficult to extrapolate from that data the actual quantitative levels of expression of the GRα and GRβ in the steroidinsensitive patients.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Glucocorticoid receptor expression and glucocorticoid therapeutic effect in nasal polyps

Li¹,

Li²,

Yang³

et al. 2010

CIM

View full text Add to dashboard Cite

Clin Invest Med 2010; 33 (3): E181-E188. AbstractPurpose: To investigate the expression and quantity of glucocorticoid receptor-α and -β in polyp tissues taken from the patients treated were subsequently treated with topical glucocorticoid (GC). Methods: Eighty patients with nasal polyps were initially enrolled in the study. All polyp specimens were obtained prior to treatment. Patients then received daily topical GC spray treatment for one month. Polyp specimens were tested for glucocorticoid receptor (GR) GR-α and GR-β mRNA expression using fluorescent quantitative-reverse transcription-polymerase chain reaction (FQ-RT-PCR). Thirty healthy nasal mucosa tissue samples were tested at the same time.

show abstract

Section: Discussionmentioning

confidence: 95%

“…[14][15][16] These conflicting results may be explained by the different methodologies used. First, immunohistochemical studies do not accurately reflect the GR-α to GR-β ratio of the cell.…”

Section: Discussionmentioning

confidence: 99%

Glucocorticoid receptor expression and glucocorticoid therapeutic effect in nasal polyps

Li¹,

Li²,

Yang³

et al. 2010

CIM

View full text Add to dashboard Cite

show abstract

“…They decrease polyp size, improve nasal airway patency, improve symptoms of rhinitis like rhinorrhoea, sneezing and nasal blockage, delay the recurrence of polyps after surgery and postpone the need for a new surgery [11]. The unusually wide range of GC actions can be explained by GC receptors present in three cell compartments: nucleus, cytoplasm, and plasma membrane.…”

Section: Medical Managementmentioning

confidence: 99%

Nasal Polyposis: Current Trends

Rajguru¹

2011

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Nasal polyps (NP) are one of the most common inflammatory mass lesions of the nose, affecting up to 4% of the population. They present with nasal obstruction, anosmia, rhinorrhoea, post nasal drip, and less commonly facial pain. Their etiology remains unclear, but they are known to have associations with allergy, asthma, infection, fungus, cystic fibrosis, and aspirin sensitivity. However, the underlying mechanisms interlinking these pathologic conditions to NP formation remain unclear. Also strong genetic factors are implicated in the pathogenesis of NP, but genetic and molecular alterations required for its development and progression are still unclear. Management of NP involves a combination of medical therapy and surgery. There is good evidence for the use of corticosteroids (systemic and topical) both as primary treatment and as postoperative prophylaxis against recurrence, but the prolonged course of the disease and adverse effects of systemic steroids limits their use. Hence several new drugs are under trial. Surgical treatment has been refined significantly over the past 20 years with the advent of endoscopic sinus surgery and, in general, is reserved for cases refractory to medical treatment. Recurrence of the polyposis is common with severe disease recurring in up to 10% of patients. Over the last two decades, increasing insights in the pathophysiology of nasal polyposis opens perspective for new pharmacological treatment options, with eosinophilic inflammation, IgE, fungi and Staphylococcus aureus as potential targets. A better understanding of the pathophysiology underlying the persistent inflammatory state in NP is necessary to ultimately develop novel pharmacotherapeutic approaches. In this paper we present the newer treatment options available for better control and possibly cure of the disease.

show abstract

“…This has led to the hypothesis that increased GR expression could impair the action of GC. Decreased expression of GR has also been recently reported in CRswNP with the use of a more reliable quantitative method of analysis [56,62,63]. More important than the expression of each individual isoform, GR -GR imbalance might be the most relevant determinant of GC resistance.…”

Section: Resistance To Gcmentioning

confidence: 99%

“…More important than the expression of each individual isoform, GR -GR imbalance might be the most relevant determinant of GC resistance. It is important to mention that some studies have demonstrated that CG therapy in CRSwNP does not change GR isoform expression or the GR -GR relation [56,63,64].…”

Section: Resistance To Gcmentioning

confidence: 99%

Glucocorticoid Resistance in the Upper Respiratory Airways

Valera¹,

Tamashiro²,

Anselmo‐Lima³

2012

Glucocorticoids - New Recognition of Our Familiar Friend

View full text Add to dashboard Cite

Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids

Abstract: GRalpha is downregulated in nasal polyps and upregulated by GC treatment. Neither GRalpha nor GRbeta appear to determine the sensitivity to GCs in nasal polyposis.

Cited by 50 publications

References 36 publications

Glucocorticoid receptor expression and glucocorticoid therapeutic effect in nasal polyps

Glucocorticoid receptor expression and glucocorticoid therapeutic effect in nasal polyps

Nasal Polyposis: Current Trends

Glucocorticoid Resistance in the Upper Respiratory Airways

Contact Info

Product

Resources

About